AU2002232222A1 - Therapeutic Agents for Inflammatory Bowel Diseases - Google Patents
Therapeutic Agents for Inflammatory Bowel DiseasesInfo
- Publication number
- AU2002232222A1 AU2002232222A1 AU2002232222A AU2002232222A AU2002232222A1 AU 2002232222 A1 AU2002232222 A1 AU 2002232222A1 AU 2002232222 A AU2002232222 A AU 2002232222A AU 2002232222 A AU2002232222 A AU 2002232222A AU 2002232222 A1 AU2002232222 A1 AU 2002232222A1
- Authority
- AU
- Australia
- Prior art keywords
- therapeutic agents
- inflammatory bowel
- bowel diseases
- diseases
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010021972 Inflammatory bowel disease Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2002232222A AU2002232222B8 (en) | 1999-08-30 | 2002-02-18 | Therapeutic Agents for Inflammatory Bowel Diseases |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11/242672 | 1999-08-30 | ||
| JP2000/254680 | 2000-08-24 | ||
| AU68650/00A AU6865000A (en) | 1999-08-30 | 2000-08-30 | Remedies for immunological diseases |
| JP2001089158 | 2001-03-27 | ||
| JP2001-89158 | 2001-03-27 | ||
| JP2002-19291 | 2002-01-29 | ||
| JP2002019291A JP4210454B2 (en) | 2001-03-27 | 2002-01-29 | Inflammatory bowel disease treatment |
| PCT/JP2002/001361 WO2002076504A1 (en) | 2001-03-27 | 2002-02-18 | Remedies for inflammatory bowel diseases |
| AU2002232222A AU2002232222B8 (en) | 1999-08-30 | 2002-02-18 | Therapeutic Agents for Inflammatory Bowel Diseases |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU68650/00A Division AU6865000A (en) | 1999-08-30 | 2000-08-30 | Remedies for immunological diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2002232222A1 true AU2002232222A1 (en) | 2003-03-27 |
| AU2002232222B2 AU2002232222B2 (en) | 2006-01-19 |
| AU2002232222B8 AU2002232222B8 (en) | 2006-05-18 |
Family
ID=26612136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002232222A Ceased AU2002232222B8 (en) | 1999-08-30 | 2002-02-18 | Therapeutic Agents for Inflammatory Bowel Diseases |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7465444B2 (en) |
| EP (1) | EP1374902B1 (en) |
| JP (1) | JP4210454B2 (en) |
| KR (1) | KR100602940B1 (en) |
| CN (1) | CN1291757C (en) |
| AT (1) | ATE510562T1 (en) |
| AU (1) | AU2002232222B8 (en) |
| BR (1) | BR0208446A (en) |
| CA (1) | CA2441577C (en) |
| CZ (1) | CZ20032692A3 (en) |
| HU (1) | HU229378B1 (en) |
| IL (2) | IL158088A0 (en) |
| MX (1) | MXPA03008760A (en) |
| NO (1) | NO332316B1 (en) |
| NZ (1) | NZ528554A (en) |
| RU (1) | RU2281118C2 (en) |
| SK (1) | SK288036B6 (en) |
| WO (1) | WO2002076504A1 (en) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7112655B1 (en) | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
| JP3521382B2 (en) | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | Cell surface molecules that mediate cell-cell adhesion and signal transduction |
| DE19821060A1 (en) * | 1997-09-23 | 1999-04-15 | Bundesrepublik Deutschland Let | T cell co-stimulating polypeptide, monoclonal antibodies, and the production and use thereof |
| JP4210454B2 (en) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | Inflammatory bowel disease treatment |
| JP3871503B2 (en) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | Immune disease treatment |
| JP3597140B2 (en) | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | Human monoclonal antibody against costimulatory molecule AILIM and pharmaceutical use thereof |
| JP4212278B2 (en) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | Graft rejection inhibitor |
| WO2004080273A2 (en) * | 2003-03-12 | 2004-09-23 | Rappaport Family Institute For Research In The Medical Sciences | Compositions and methods for diagnosing and treating prostate cancer |
| US8017113B2 (en) | 2003-03-12 | 2011-09-13 | Rappaport Family Institute For Research In The Medical Sciences | Compositions and methods for diagnosing and treating an inflammation |
| ES2442386T3 (en) * | 2004-04-23 | 2014-02-11 | Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Pr | Method for the treatment of conditions mediated by T cells by the decrease of positive ICOS cells in vivo. |
| SI1915398T1 (en) * | 2005-07-18 | 2016-07-29 | Amgen Inc. | Human anti-b7rp1 neutralizing antibodies |
| AU2013203437A1 (en) * | 2005-07-18 | 2013-05-02 | Amgen Inc. | Human anti-B7RP1 neutralizing antibodies |
| US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| LT2364360T (en) | 2008-11-13 | 2017-08-10 | Nogra Pharma Limited | Antisense compositions and methods of making and using same |
| EP2691419B1 (en) * | 2011-03-31 | 2016-11-09 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antibodies directed against icos and uses thereof |
| CA2841416A1 (en) * | 2011-06-15 | 2012-12-20 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of selecting therapeutic indications |
| MD480Z5 (en) * | 2011-07-07 | 2012-09-30 | Эльвира АНДОН | Method for treating acute ulcerative nonspecific colitis |
| US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
| JOP20140087B1 (en) | 2013-03-13 | 2021-08-17 | Amgen Inc | Proteins specific for baff and b7rp1 and uses thereof |
| AU2014230741B2 (en) | 2013-03-15 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Anti-LAG-3 binding proteins |
| MA41414A (en) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | ICOS AGONIST BINDING PROTEINS |
| ES2842306T3 (en) | 2015-09-02 | 2021-07-13 | Immutep Sas | Anti LAG-3 antibodies |
| RU2722019C2 (en) | 2015-12-03 | 2020-05-26 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Cyclic purine dinucleotides as modulators of sting |
| WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
| RU2018137389A (en) | 2016-04-07 | 2020-05-12 | Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Heterocyclic amides useful as modulators |
| IL295649A (en) | 2016-04-07 | 2022-10-01 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators |
| PE20190106A1 (en) | 2016-05-05 | 2019-01-15 | Glaxosmithkline Ip No 2 Ltd | ZESTE APPROVAL ENHANCER INHIBITORS 2 |
| EP3487503A1 (en) | 2016-07-20 | 2019-05-29 | GlaxoSmithKline Intellectual Property Development Limited | Isoquinoline derivatives as perk inhibitors |
| BR112019017738A2 (en) | 2017-02-27 | 2020-04-07 | Glaxosmithkline Ip Dev Ltd | combination, pharmaceutical composition, use of a combination or pharmaceutical composition, method for treating cancer in a human, and, compound |
| TWI788340B (en) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | Anti-icos agonist antibodies and uses thereof |
| US20200190195A1 (en) | 2017-06-09 | 2020-06-18 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy with icos agonist and ox40 agonist to treat cancer |
| US20200181275A1 (en) | 2017-06-09 | 2020-06-11 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy with icos agonist and ox40 agonist to treat cancer |
| EP3634483A1 (en) | 2017-06-09 | 2020-04-15 | GlaxoSmithKline Intellectual Property Development Limited | Combination therapy |
| WO2019021208A1 (en) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | Indazole derivatives useful as perk inhibitors |
| WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
| EP3692066A2 (en) | 2017-09-14 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatment for cancer |
| CA3077337A1 (en) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) |
| TW201927771A (en) | 2017-10-05 | 2019-07-16 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | Heterocyclic amides useful as protein modulators and methods of using the same |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| JP2021525271A (en) | 2018-05-31 | 2021-09-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Combined therapy with ICOS-binding protein and arginine methyltransferase inhibitor |
| BR112020023451A2 (en) | 2018-05-31 | 2021-02-23 | Glaxosmithkline Intellectual Property Development Limited | combination therapy |
| KR20210035805A (en) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | Increased immune activity through regulation of postcellular signaling factors |
| WO2020031087A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
| AU2019366321A1 (en) | 2018-10-22 | 2021-05-13 | Glaxosmithkline Intellectual Property Development Limited | Dosing |
| MA55805A (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | METHODS OF MODULATING IMMUNE ACTIVITY |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| WO2021018941A1 (en) | 2019-07-31 | 2021-02-04 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
| WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
| WO2021046293A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab |
| CN114729049A (en) | 2019-09-27 | 2022-07-08 | 葛兰素史密斯克莱知识产权发展有限公司 | Antigen binding proteins |
| JP2023509359A (en) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | Combination anticancer therapy with inducers of iron-dependent cell degradation |
| US20230149543A1 (en) | 2020-04-14 | 2023-05-18 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer based upon an icos antbody and a pd-l1 antibody tgf-bets-receptor fusion protein |
| US20230140694A1 (en) | 2020-04-14 | 2023-05-04 | GlaxoSmithKline Intellectual Property Developement Limited | Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies |
| AU2021257570A1 (en) | 2020-04-14 | 2022-11-03 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
| CN116096906A (en) | 2020-06-29 | 2023-05-09 | 旗舰创业创新五公司 | Virus engineered to promote saenox delivery and use thereof in treating cancer |
| BR112023017296A2 (en) | 2021-03-02 | 2023-11-14 | Glaxosmithkline Ip Dev Ltd | SUBSTITUTED PYRIDIINES AS DNMT1 INHIBITORS |
| BR112023018308A2 (en) * | 2021-03-12 | 2023-10-31 | Adaptive Biotechnologies Corp | METHODS RELATED TO THE T CELL RECEPTOR ASSOCIATED WITH CROHN'S DISEASE |
| KR20230165276A (en) | 2021-03-31 | 2023-12-05 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | Thanotransmission polypeptides and their use in the treatment of cancer |
| US20240166747A1 (en) | 2021-03-31 | 2024-05-23 | Glazosmithkline Intellectual Property Development Limited | Antigen binding proteins and combinations thereof |
| US20220396623A1 (en) | 2021-05-18 | 2022-12-15 | Kymab Limited | Uses of anti-icos antibodies |
| EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2023222854A1 (en) | 2022-05-18 | 2023-11-23 | Kymab Limited | Uses of anti-icos antibodies |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506126A (en) * | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
| US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6641809B1 (en) * | 1990-03-26 | 2003-11-04 | Bristol-Myers Squibb Company | Method of regulating cellular processes mediated by B7 and CD28 |
| US5770197A (en) * | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
| JP3162438B2 (en) | 1991-09-12 | 2001-04-25 | 住友製薬株式会社 | Highly sensitive specific antibody assay |
| US5484892A (en) * | 1993-05-21 | 1996-01-16 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells |
| US6719972B1 (en) * | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
| US5747461A (en) * | 1994-07-26 | 1998-05-05 | Markov; Angel K. | Synergistic administration of cyclosporine and fructose diphosphate |
| EP1297847A3 (en) | 1996-01-23 | 2003-05-07 | Genentech, Inc. | Anti-CD18 antibodies in stroke |
| US5914112A (en) * | 1996-01-23 | 1999-06-22 | Genentech, Inc. | Anti-CD18 antibodies in stroke |
| DK0928197T3 (en) | 1996-09-18 | 2003-06-23 | Zetesis Spa | Use of proteins as agents for autoimmune diseases |
| BR9713498A (en) * | 1996-11-08 | 2000-02-29 | Idec Pharma Corp | Identification of unique binding interactions between some antibodies and human co-stimulatory antigens b7.1 and b7.2 |
| AU4145597A (en) | 1997-02-20 | 1998-09-09 | Cedars-Sinai Medical Center | Ulcerative colitis panca secretory vesicle antigen and methods of using sa me |
| US7112655B1 (en) | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
| JP3521382B2 (en) | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | Cell surface molecules that mediate cell-cell adhesion and signal transduction |
| WO2001018022A1 (en) | 1999-09-03 | 2001-03-15 | Human Genome Sciences, Inc. | 52 human secreted proteins |
| DE69829891T2 (en) | 1997-04-07 | 2005-10-06 | Genentech, Inc., South San Francisco | Anti-VEGF antibody |
| DE19821060A1 (en) * | 1997-09-23 | 1999-04-15 | Bundesrepublik Deutschland Let | T cell co-stimulating polypeptide, monoclonal antibodies, and the production and use thereof |
| ES2279585T3 (en) * | 1997-09-23 | 2007-08-16 | Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts | COESTIMULANT T-CELL POLYPEPTIDE, MONOCLONAL ANTIBODIES, ITS PREPARATION AND USE. |
| JPH11228442A (en) | 1998-02-09 | 1999-08-24 | Cypros Pharmaceut Corp | Use of fructose diphosphate for reducing cyclosporin dose after organ transplantation |
| AU767241B2 (en) * | 1998-09-14 | 2003-11-06 | Qiang Xu | Immunosuppressive agents |
| JP2000154151A (en) * | 1998-09-14 | 2000-06-06 | Kyo Jo | Immunosuppressant |
| WO2000019988A1 (en) | 1998-10-07 | 2000-04-13 | Millennium Pharmaceuticals, Inc. | NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF |
| NZ551331A (en) | 1999-02-03 | 2008-08-29 | Amgen Inc | Methods using polypeptides involved in immune response |
| US7708993B2 (en) * | 1999-02-03 | 2010-05-04 | Amgen Inc. | Polypeptides involved in immune response |
| AU4825700A (en) | 1999-05-06 | 2000-11-21 | Genetics Institute Inc. | Use of soluble costimulatory molecules to enhance immune responses |
| AU6615500A (en) | 1999-07-28 | 2001-02-19 | Genetics Institute Inc. | Preventing immune-mediated abortion by inhibiting costimulation |
| WO2001012658A2 (en) | 1999-08-11 | 2001-02-22 | Isis Innovations Limited | Human icos ligand and application thereof |
| JP4210454B2 (en) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | Inflammatory bowel disease treatment |
| JP3871503B2 (en) * | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | Immune disease treatment |
| PT1218504E (en) | 1999-09-21 | 2007-10-22 | Genetics Inst Llc | Gl50 molecules and uses therefor |
| JP2003528586A (en) | 1999-10-29 | 2003-09-30 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | 32 human secreted proteins |
| WO2001064704A1 (en) | 2000-03-02 | 2001-09-07 | Mayo Foundation For Medical Education And Research | hB7-H2, A NOVEL CO-STIMULATORY MOLECULE |
| JP3597140B2 (en) | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | Human monoclonal antibody against costimulatory molecule AILIM and pharmaceutical use thereof |
| EP1337634A2 (en) | 2000-11-28 | 2003-08-27 | Amgen Inc. | Novel polypeptides involved in immune response |
| JP4212278B2 (en) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | Graft rejection inhibitor |
| US7428905B2 (en) * | 2004-07-30 | 2008-09-30 | R.J. Reynolds Tobacco Company | Method of making smokeable tobacco substitute filler having an increased fill value |
-
2002
- 2002-01-29 JP JP2002019291A patent/JP4210454B2/en not_active Expired - Fee Related
- 2002-02-18 CN CNB028107470A patent/CN1291757C/en not_active Expired - Fee Related
- 2002-02-18 CZ CZ20032692A patent/CZ20032692A3/en unknown
- 2002-02-18 EP EP02712418A patent/EP1374902B1/en not_active Expired - Lifetime
- 2002-02-18 SK SK1330-2003A patent/SK288036B6/en not_active IP Right Cessation
- 2002-02-18 RU RU2003131330/15A patent/RU2281118C2/en active
- 2002-02-18 AU AU2002232222A patent/AU2002232222B8/en not_active Ceased
- 2002-02-18 NZ NZ528554A patent/NZ528554A/en not_active IP Right Cessation
- 2002-02-18 US US10/472,743 patent/US7465444B2/en not_active Expired - Fee Related
- 2002-02-18 IL IL15808802A patent/IL158088A0/en unknown
- 2002-02-18 KR KR1020037012380A patent/KR100602940B1/en not_active IP Right Cessation
- 2002-02-18 MX MXPA03008760A patent/MXPA03008760A/en active IP Right Grant
- 2002-02-18 CA CA2441577A patent/CA2441577C/en not_active Expired - Fee Related
- 2002-02-18 AT AT02712418T patent/ATE510562T1/en not_active IP Right Cessation
- 2002-02-18 HU HU0303622A patent/HU229378B1/en not_active IP Right Cessation
- 2002-02-18 BR BR0208446-5A patent/BR0208446A/en not_active Application Discontinuation
- 2002-02-18 WO PCT/JP2002/001361 patent/WO2002076504A1/en active IP Right Grant
-
2003
- 2003-09-24 IL IL158088A patent/IL158088A/en not_active IP Right Cessation
- 2003-09-26 NO NO20034312A patent/NO332316B1/en not_active IP Right Cessation
-
2008
- 2008-11-11 US US12/268,882 patent/US8052972B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002232222A1 (en) | Therapeutic Agents for Inflammatory Bowel Diseases | |
| HUP0303622A3 (en) | Emedies for inflammatory bowel diseases | |
| GB9911863D0 (en) | Therapeutic agents | |
| GB9905010D0 (en) | Therapeutic agents | |
| IL150030A0 (en) | Therapeutic agents | |
| GB9904786D0 (en) | Therapeutic agents | |
| GB9929685D0 (en) | Therapeutic agents | |
| AU2446801A (en) | Treatment for inflammatory bowel disease (ibd) and related conditions | |
| GB9929687D0 (en) | Therapeutic agents | |
| IL146130A0 (en) | Anti-inflammatory therapy for inflammatory mideated infection | |
| GB9921351D0 (en) | Therapeutic agents | |
| GB9911881D0 (en) | Therapeutic agents | |
| AU2451500A (en) | Therapeutic agents | |
| GB9929569D0 (en) | Therapeutic agents | |
| GB9914744D0 (en) | Therapeutic agents | |
| EP1444983A4 (en) | Agents for treating inflammatory bowel diseases | |
| GB9903119D0 (en) | Therapeutic agents | |
| AU5973600A (en) | Therapeutic agents | |
| IL147078A0 (en) | Therapeutic agents | |
| GB9902881D0 (en) | Therapeutic agents | |
| AU6150200A (en) | Therapeutic agents | |
| AU5817400A (en) | Therapeutic agents | |
| AU2001292306A1 (en) | Remedies for inflammatory bowel diseases | |
| AU6302300A (en) | Therapeutic agents | |
| AU5817500A (en) | Therapeutic agents |